CDC7 is a targetable regulator of advanced prostate cancer
Alifiani B. Hartono, HyeonJi Hwang, Sidharth Paparaju, Shiqin Liu, James D. Brooks, Eva Corey, Tanya Stoyanova · 2025
Read CDC7 is a targetable regulator of advanced prostate cancer by Alifiani B. Hartono, HyeonJi Hwang, Sidharth Paparaju, Shiqin Liu, James D. Brooks, Eva Corey, Tanya Stoyanova (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12770614.txt.
Description
Alifiani Hartono and co-authors name a drug target in advanced prostate cancer in a 2025 study. Prostate cancer kills tens of thousands of men in the United States each year, mostly once it spreads. The protein CDC7, which helps start DNA copying, rises as these cancers turn treatment-resistant and take on a nerve-like form. The team tested what happens when it is blocked.
Lowering CDC7 slowed cancer cell growth and invasion in dishes and shrank tumors in animals. A selective blocker drug also cut growth, movement, and invasion of aggressive cells. Treated cells showed a warped cell cycle, a sign of copying stress, and more cell death. The authors say CDC7 drives tumor progress in this setting. They propose it as a fresh drug target for resistant disease.
Catalog record
| CREATOR | Alifiani B. Hartono, HyeonJi Hwang, Sidharth Paparaju, Shiqin Liu, James D. Brooks, Eva Corey, Tanya Stoyanova |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |